Biogen Braces For Cost Cuts As Business Transition Continues
The company announced a new $1bn cost savings program that will result in 1,000 job cuts; $300m of the savings will be reinvested in new drug launches and R&D.
The company announced a new $1bn cost savings program that will result in 1,000 job cuts; $300m of the savings will be reinvested in new drug launches and R&D.